13F Holdings
中文EN

BAX BAXTER INTERNATIONAL INC

Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 10456 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY5.3%
TTM net income YoY-112.0%
TTM EPS YoY-115.2%
Revenue 3-yr CAGR0.7%
Net income 3-yr CAGR—

Margins

Gross margin30.1%
Operating margin-1.9%
Net margin-6.2%
FCF margin—
EBITDA margin3.8%

Returns

ROE-10.5%
ROA-3.6%
ROIC (approx.)-3.5%
Asset turnover0.57x

Leverage & solvency

Liabilities / assets66.6%
Debt / equity0.00x
Current ratio1.79x
Interest coverage-0.75x

Cash quality & payout

Operating cash flow / net income-2.27x
Accruals ratio-11.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$11.24B$10.64B$10.36B$10.06B$12.15B
Cost of revenue$7.87B$6.65B$6.21B$6.51B$7.43B
Gross profit$3.38B$3.98B$4.15B$3.55B$4.72B
R&D expense$518.00M$590.00M$518.00M$450.00M$531.00M
SG&A expense$2.89B$2.97B$2.95B$3.10B$2.85B
Operating income-$308.00M$14.00M$707.00M-$2.85B$1.35B
Interest expense$290.00M$408.00M$508.00M$413.00M$207.00M
Pretax income-$505.00M-$289.00M$242.00M-$3.25B$1.12B
Income tax$395.00M$37.00M$61.00M-$135.00M$83.00M
Net income-$957.00M-$649.00M$2.66B-$2.43B$1.28B
EBITDA$673.00M$1.01B$1.69B-$1.77B$2.22B
EPS (basic)-1.87-1.275.25-4.832.56
EPS (diluted)-1.87-1.275.23-4.832.53
Dividends declared per share0.521.041.161.151.08
Weighted avg. shares (diluted)513.00M510.00M508.00M504.00M508.00M
Banking
Net interest income——-$442.00M-$395.00M-$193.00M
Balance sheet
Cash & equivalents$1.97B$1.76B$3.08B$1.62B$2.95B
Receivables$1.86B$1.68B$1.72B$2.57B$2.63B
Inventory$2.23B$2.05B$1.92B$2.68B$2.45B
Current assets$6.87B$8.85B$9.60B$8.01B$8.87B
PP&E, net$2.91B$2.87B$2.87B$4.70B$5.18B
Goodwill$4.93B$5.28B$5.79B$6.45B$9.84B
Intangibles$4.37B$5.22B$5.92B$6.79B$7.79B
Total assets$20.05B$25.78B$28.28B$28.29B$33.52B
Current liabilities$2.97B$6.51B$6.50B$4.75B$4.24B
Short-term debt$1.00M$2.13B$0$299.00M$301.00M
Long-term debt$9.47B$10.37B$11.09B$15.23B$17.15B
Total debt$9.47B$12.50B$11.09B$15.53B$17.45B
Total liabilities$13.95B$18.76B$19.81B$22.39B$24.40B
Shareholders' equity$6.13B$6.96B$8.40B$5.83B$9.08B
Net debt$7.51B$10.74B$8.01B$13.91B$14.50B
Cash flow statement
Operating cash flow$845.00M$1.02B$1.73B$1.21B$2.22B
Capital expenditure$513.00M$446.00M$432.00M$377.00M$691.00M
Free cash flow$332.00M$573.00M$1.29B$834.00M$1.53B
Investing cash flow$2.84B-$626.00M$3.21B-$931.00M-$11.20B
Financing cash flow-$4.22B-$1.08B-$3.49B-$1.44B$8.24B
Depreciation & amortization$981.00M$997.00M$984.00M$1.07B$867.00M
Stock-based compensation$117.00M$114.00M$115.00M$140.00M$146.00M
Dividends paid$348.00M$590.00M$586.00M$573.00M$530.00M
Share buybacks—$0$0$32.00M$600.00M

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.